Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor

Published:2014 Issue: Volume: Page:81-97
ISSN:0080-0015
Container-title:Recent Results in Cancer Research
language:
Short-container-title:

Author:

Isfort Susanne,Amsberg Gunhild Keller-v.,Schafhausen Philippe,Koschmieder Steffen,Brümmendorf Tim H.

Publisher

Springer Berlin Heidelberg

Link

http://link.springer.com/content/pdf/10.1007/978-3-642-54490-3_4

Reference44 articles.

1. Baccarani M, Cortes J et al (2013) European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013 Blood 2013 prepublished online 26 June 2013. doi: 10.1182/blood-2013-05-501569

2. Bartolovic K, Balabanov S et al (2004) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103(2):523–529

3. Boschelli DH, Ye F et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Srckinaseactivity. J Med Chem 44(23):3965–3977

4. Boschelli F (2008) Activity of bosutinib, dasatinib, and nilotinibagainst 18 imatinib-resistantBcr/Ablmutants. doi: 10.1200/JCO.2008.19.8853

5. Bruemmendorf TH, Kantarjian HM et al (2012) Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120:69

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?;Cancers;2024-08-28

2. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges;MedComm;2023-12

3. Synthesis and Cytotoxicity Evaluation of Novel Coumarin–Palladium(II) Complexes against Human Cancer Cell Lines;Pharmaceuticals;2022-12-29

4. A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors;Current Oncology;2022-12-03

5. Semi-Synthesis, Cytotoxic Evaluation, and Structure—Activity Relationships of Brefeldin A Derivatives with Antileukemia Activity;Marine Drugs;2021-12-24